Phase III ACTIVE trial of BA 058 (abaloparatide) in osteoporosis published in JAMA- Radius Health
Radius Health has announced that positive results from the Phase III ACTIVE trial of BA 058 (abaloparatide) in osteoporosis were published in the Journal of the American Medical Association (JAMA). This landmark trial enrolled 2,463 patients to evaluate the safety and efficacy of investigational drug abaloparatide for the treatment of postmenopausal women with osteoporosis. The ACTIVE results showed that patients treated with daily abaloparatide for 18 months had a significantly greater reduction in the incidence of new vertebral fractures and nonvertebral fractures compared to placebo.
See: " Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisA Randomized Clinical Trial" Paul D. Miller et al. JAMA. 2016;316(7):722-733. doi:10.1001/jama.2016.11136
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins